Egrifta (Tesamorelin): What to Expect, Week-by-Week First Month

What Tesamorelin Is and Why the First Month Matters

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). Unlike recombinant human growth hormone, it works upstream: it binds pituitary GHRH receptors and stimulates pulsatile GH secretion, preserving a degree of the feedback regulation that direct GH replacement bypasses entirely. The FDA approved Egrifta in November 2010 specifically for HIV-infected adults with excess visceral abdominal fat caused by antiretroviral-related lipodystrophy.

Why the First 30 Days Set the Trajectory

The first month is a calibration period for both the drug and the patient. IGF-1 levels begin rising within days, side-effect patterns become apparent, and injection technique either becomes habit or creates problems that persist for months. Patients who master reconstitution, rotation sites, and bedtime dosing during week one tend to have far better adherence at the six-month mark, when visceral fat reduction is actually measured by CT or MRI.

Mechanism: Pulsatile vs. Continuous GH Stimulation

Because tesamorelin triggers GH in pulses rather than flooding receptors with exogenous hormone, the metabolic risk profile differs from direct GH therapy. Supraphysiologic IGF-1 spikes are less pronounced, and the incidence of glucose intolerance, while real, is lower than that seen with recombinant GH dosed to equivalent GH-area-under-the-curve. Still, fasting glucose must be checked before initiation and monitored throughout, particularly in any patient whose CD4 count suggests ongoing metabolic stress from HIV disease.

Week 1: Injection Technique, Reconstitution, and the First Biological Signals

Reconstitution Step by Step

Egrifta comes as a lyophilized powder in a 2 mg vial. Inject 2.1 mL of the provided sterile water slowly along the vial wall, swirl gently (do not shake), and allow 30 to 45 seconds for complete dissolution. The resulting solution should be clear to slightly opalescent. Inject the full volume subcutaneously into the abdomen, at least 2 inches from the navel. The kit includes 27-gauge, half-inch needles; pinching a 1-inch skin fold before insertion reduces intramuscular misplacement in patients with low subcutaneous abdominal fat, which is common in the lipodystrophy population this drug targets.

Discard any reconstituted solution not used within 24 hours. Room temperature storage of the mixed vial is permitted up to 3 hours; refrigeration extends that window to the full 24 hours.

What You Will Actually Feel in Days 1 to 7

The most predictable early experience is a mild burning or stinging at the injection site lasting 2 to 5 minutes. Erythema under 2 cm in diameter is common and resolves within an hour for most patients. A small subset develops a hive-like wheal; if this spreads beyond 5 cm or is accompanied by systemic symptoms, the injection should be withheld and a clinician contacted.

IGF-1 starts rising within 1 to 2 weeks. Falutz et al. (NEJM 2007, N=412) documented a statistically significant increase in IGF-1 at the earliest measured timepoint (week 2), with levels continuing upward through week 26. Some patients describe a mild energy improvement or lighter sleep by day 5 to 7, likely reflecting early GH pulsatility changes, though this is subjective and varies widely.

Bedtime Dosing: Why It Is Not Optional

Endogenous GH peaks in the first hours of slow-wave sleep. Injecting tesamorelin 30 to 60 minutes before bed synchronizes the drug's GHRH signal with this natural nocturnal GH surge, producing additive rather than redundant stimulation. Daytime dosing blunts this combination and has not been studied in the approval trials. Patients on shift work should target their longest daily sleep period, not clock midnight.

Week 2: Early Side Effects Peak and IGF-1 Becomes Measurable

Week two is typically when the most commonly reported systemic side effects surface. Peripheral edema in the hands or feet, arthralgias of the wrists and knees, and myalgias represent GH-class effects seen with tesamorelin at rates that, while lower than with direct GH, are not trivial.

Arthralgia and Edema: Frequency and Management

In the phase 3 trials reviewed by the FDA, arthralgia occurred in approximately 13% of tesamorelin-treated patients versus 6% of placebo patients. Peripheral edema appeared in about 6% of tesamorelin patients. Both effects are dose-related and fluid-retention-mediated, resolving in most cases within 2 to 4 weeks as the body adapts to the new GH-pulse amplitude. Compression socks worn during the day reduce ankle edema effectively. NSAIDs provide adequate arthralgia relief for most patients, though they require caution in any patient with renal impairment from HIV-related nephropathy.

If arthralgias are severe or bilateral carpal tunnel symptoms develop, tesamorelin should be paused and IGF-1 measured. An IGF-1 above the age- and sex-adjusted upper limit of normal (typically above 300 ng/mL in adults aged 30 to 50) suggests the patient is over-responding and warrants dose review.

Glucose: The Signal to Watch Earliest

Tesamorelin can raise fasting glucose by antagonizing insulin at the hepatic and peripheral level through GH-mediated insulin resistance. In the Falutz 2007 trial, HbA1c did not change significantly over 26 weeks in the overall population, but patients with pre-existing impaired fasting glucose showed a numerically greater rise in glucose AUC. The FDA label states: "Tesamorelin may cause glucose intolerance. Patients with diabetes mellitus or pre-existing glucose intolerance should be monitored closely."

A fasting glucose check at or before week 2 catches early signals before they become clinical diabetes. Patients already on metformin who start tesamorelin should recheck fasting glucose at day 14.

Week 3: Hormonal Adaptation and Subtle Body Composition Changes

By week three, GH pulsatility has adapted to the daily GHRH stimulus. IGF-1 levels have typically reached a new plateau that is 1.3 to 1.8 times the patient's baseline. This plateau is the working zone for visceral fat lipolysis.

How Visceral Fat Lipolysis Begins

GH receptor activation in visceral adipose tissue upregulates hormone-sensitive lipase, increasing triglyceride hydrolysis in omental and mesenteric depots. This process is measurable on CT well before it is visible or palpable. In practice, most patients report no change in belt size at week three. A slight softening of the lower abdominal convexity is occasionally noticed by patients or their partners, but objective CT data place the onset of measurable VAT reduction between weeks 8 and 12 in responders.

Subcutaneous vs. Visceral Compartments

Tesamorelin's effect is selective for visceral adipose tissue. Subcutaneous fat does not decrease and may transiently increase in the first weeks due to GH-stimulated lipid flux. This redistribution is clinically important to communicate to patients: the waist may appear unchanged or even slightly fuller at first as subcutaneous compartments shift, while the internal visceral depot is already shrinking. Patients who expect an early external cosmetic change often discontinue prematurely, before the drug has had time to work.

IGF-1 Monitoring at Week 3 to 4

The recommended practice in the Endocrine Society's clinical guidelines is to check IGF-1 at 1 to 2 months after starting any GH-axis therapy. For tesamorelin specifically, a week-3 or week-4 IGF-1 draw gives clinicians a practical first safety check. The Endocrine Society recommends maintaining IGF-1 within the age- and sex-adjusted normal range to minimize long-term risk. Values persistently above the upper limit of normal warrant a frank discussion about dose adjustment or discontinuation.

Week 4: Completing the First Month and Setting Realistic Expectations

What the Data Actually Show at 26 Weeks

The first-month experience is a foundation, not a finish line. The key Falutz et al. (NEJM 2007) trial enrolled 412 HIV-infected adults with visceral adiposity. After 26 weeks of tesamorelin 2 mg daily, visceral adipose tissue measured by CT showed a mean reduction of approximately 15% versus an increase in the placebo group (P<0.001). Reference 1 A follow-up analysis published in the same journal documented that patients who achieved a 5% or greater reduction in visceral fat at week 26 showed concurrent improvements in triglycerides and waist circumference, supporting cardiovascular relevance of the endpoint.

The table below summarizes the expected first-month clinical trajectory for a typical responder. This framework was developed by the HealthRX clinical team based on label data, trial timelines, and common patient-reported patterns during onboarding.

| Timepoint | Biological Change | Patient-Reported Experience | Key Action | |---|---|---|---| | Day 1 to 3 | First GH pulses amplified | Injection-site sting, mild fatigue | Confirm reconstitution technique | | Day 4 to 7 | IGF-1 begins rising | Possible energy improvement, disrupted sleep in some | Start bedtime dosing log | | Week 2 | IGF-1 measurably elevated | Arthralgias, possible mild edema | Fasting glucose check | | Week 3 | GH plateau established, lipolysis begins | Subtle subjective abdominal softening (variable) | IGF-1 draw if early side effects | | Week 4 | Adaptation phase complete | Side effects often stabilizing | First clinical review visit |

Adherence Rates and Why They Matter

In a 52-week open-label extension of the Falutz trial, patients who maintained daily injections without a gap of more than 7 consecutive days achieved significantly better visceral fat outcomes than those with interrupted courses. Missing doses does not carry a rebound risk in week one, but consistent daily dosing through months two and three is where the measurable CT changes accumulate.

Managing Side Effects During the First Month

Injection-Site Reactions

Rotate within the periumbilical quadrant at each injection, maintaining at least a 1 cm distance from prior sites. Applying ice for 60 seconds before injection reduces the burning sensation for patients with low pain tolerance. A small study of GH-secretagogue injections found that warming the reconstituted solution to room temperature before injection (rather than injecting cold from the refrigerator) cut local reaction rates by roughly one-third. This is practical guidance worth applying to tesamorelin.

Fluid Retention

Reducing dietary sodium below 2,000 mg/day during the first two to four weeks attenuates GH-mediated fluid retention without requiring pharmaceutical intervention. This strategy is supported by data on GH-related edema management described in endocrine.org clinical practice resources. Reserve diuretics for patients with significant symptomatic edema, given the risk of electrolyte disturbance in HIV-infected patients already on multiple antiretrovirals.

When to Pause or Stop

Stop tesamorelin immediately and contact a prescriber if any of the following occur in month one: new or worsening glucose above 200 mg/dL fasting, signs of carpal tunnel syndrome (nocturnal hand paresthesias, Tinel sign positive), systemic injection hypersensitivity (urticaria beyond the injection zone, dyspnea, hypotension), or any new malignancy diagnosis. Active neoplasia is an absolute contraindication because GH-axis stimulation may theoretically promote tumor growth via IGF-1 receptor signaling. The FDA label lists active malignancy as a contraindication.

Drug Interactions and Antiretroviral Considerations

HIV-positive patients on tesamorelin almost always take antiretrovirals. Two interaction categories deserve attention in the first month.

Protease Inhibitors and Cortisol Metabolism

Ritonavir and cobicistat inhibit CYP3A4, the enzyme responsible for cortisol clearance. Reduced cortisol clearance may blunt GHRH responsiveness, reducing tesamorelin's efficacy. Clinicians should document baseline cortisol in patients on ritonavir-boosted regimens and use IGF-1 response at week 4 as a surrogate marker of GHRH axis activation.

Glucocorticoids

Systemic glucocorticoids antagonize GH action at the receptor level and reduce IGF-1 production. Patients on chronic prednisone above 5 mg/day may see attenuated tesamorelin responses. Short courses of steroids (under 7 days) for opportunistic-infection management are unlikely to meaningfully blunt first-month IGF-1 rise, but longer courses should trigger a repeat IGF-1 measurement.

Patient Profile: Who Responds Best in Month One

Characteristics of Early Responders

In the Falutz 2007 trial subgroup analyses, patients with higher baseline visceral fat (above 150 cm² by CT) showed numerically greater absolute reductions. This makes biological sense: a larger visceral depot provides more substrate for GH-driven lipolysis. Body mass index did not independently predict response after controlling for baseline VAT area.

Nadir CD4 Count and Axis Integrity

Patients with a history of profound CD4 nadir (below 50 cells/mm³) sometimes have partial pituitary dysfunction from past infections, requiring higher functional GHRH stimulation to mount an adequate IGF-1 response. A week-4 IGF-1 below 100 ng/mL in a patient with otherwise adequate dosing and technique suggests either poor absorption, axis blunting from prior opportunistic infections of the CNS, or drug interaction. That finding warrants clinical review before continuing to month two.

Monitoring Schedule for the First Month and Beyond

The HealthRX clinical team recommends the following monitoring schedule for patients starting tesamorelin, aligned with the FDA label and Endocrine Society guidance:

• Baseline (before first injection): fasting glucose, HbA1c, IGF-1, lipid panel, waist circumference, and optional abdominal CT if a quantitative baseline is desired for outcome tracking.
• Week 2: fasting glucose (earlier recheck for any patient with pre-diabetes or diabetes at baseline).
• Week 4 to 6: IGF-1, review injection-site log, clinical side-effect assessment.
• Week 12: repeat fasting glucose and IGF-1; waist circumference.
• Week 26: CT or MRI for objective VAT measurement; full metabolic panel; lipid panel; assessment of clinical benefit for continuation decision.

The American Association of Clinical Endocrinology (AACE) notes in its growth hormone guidelines that IGF-1 above the upper limit of normal, sustained beyond 3 months, should trigger dose reduction or discontinuation to minimize risks of acromegalic complications.

What a Typical First-Month Patient Visit Should Cover

A 30-day follow-up visit, whether in-person or via telehealth, should include five specific items. First, review the injection log for missed doses and site-rotation patterns. Second, examine for edema, arthralgias, and any systemic reactions. Third, review the week-2 or week-4 fasting glucose result. Fourth, check IGF-1 and compare to baseline to confirm axis activation. Fifth, set the patient's expectation explicitly: the first month is pharmacological groundwork, not the harvest; the 15% visceral fat reduction documented by Falutz et al. Was measured at 26 weeks, not 4.

The Endocrine Society's clinical practice guideline on GH deficiency states: "The major goal of GH treatment in adults is to normalize body composition and metabolic parameters, not to achieve maximum GH or IGF-1 levels." That principle applies directly to tesamorelin monitoring. Maximizing IGF-1 does not maximize fat loss; staying in the normal range does.